



Available online on 15.1.2019 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
An International Peer Reviewed Journal
 Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial Share Alike 4.0 License which permits unrestricted non commercial use, provided the original work is properly cited
Volume 3, Issue 6, 2018



REVIEW ARTICLE

VITAMIN A, RETINOIC ACID AND TAMIBAROTENE, A FRONT TOWARD ITS ADVANCES: A REVIEW

George Zhu¹ , Ali Gamal Ahmed Al-kaf² 

¹The Institute of Oncology, Tehran University of Medical Sciences, Tehran, Iran.

²Faculty of pharmacy-Medicinal Chemistry Department, Sana'a University, Yemen.

ABSTRACT

Vitamin A and its derivative retinoic acid (13-cis RA, 9-cis RA, all-trans RA) and recent tamibarotene have been shown a broad variety of biological actives in human, such as vision, embryonic development, cell growth and cellular differentiation and immune function. These precise functions of RA are mediated by their retinoic acid receptors (RARs). In the past five decades, retinoic acid (RA) proved therapeutic benefits in cancer prevention, in skin diseases and in acute promyelocytic leukemia (APL). The elucidation of the molecular basis of vitamin A acid and its retinoid pharmacology in APL has been illustrated in several publications, the detail molecular model of gene regulation had also been proposed by Zhu in earlier 90s. A molecular model is further revised. As an approach to APL treatment, one possible the action of retinoic acid (RA), A consensus sequence (TCAGGTCA motif) has been postulated for thyroid hormone (TRE) and retinoic acid responsive element (RARE)-containing in the promoter region of target genes. High dose of RA-RARE-PML/RARa complexes in intracellular localization appears to relieve repressors from DNA-bound receptor, including the dissociation of co-repressor complexes N-CoR, SMRT and HDACs from PML-RARa or PML-RARa/RXR. Also release PML/RARa-mediated transcription repression. This transcriptional derepression occurs at RARa target gene promoter. Consequentially, PML-RARa chimera converted receptor from a repressor to a RA-dependent activator of transcription. The resulting pml-RARa oncoprotein proteolytic degradation occurs through the autophagy-lysosome pathway and the ubiquitin SUMO-proteasome system (UPS) as well as caspase 3, or lysosomal protease (cathepsin D) enzyme or/and E1-like ubiquitin-activating enzyme (UBE1L) induction. Accordingly the expression level of PML-RARa down regulated. PML protein relocalizes into the wild-type nuclear body (PML-NB) configuration or a truncated PML-RARa fusion fragment detected or/and the wild-type RAR upregulated. An effect is to relieve the blockade of pml/RARa-mediated RA dependent promyelocytic differentiation, and retinoic acid (9-cis RA, ATRA, Am80) in APL therapy. Here, oncogenic pml/RARa as constitutive transcriptional repressor that blocks myeloid differentiation at promyelocytic phenotype. RA can overcome the transcriptional repressor activity of pml/RARa. The oncogenic pml/RARa uncovers a pathogenic role in leukemogenesis of APL through blocking promyelocytic differentiation. This oncogenic receptor derivative pml/RARa chimera is locked in their "off" regular mode thereby constitutively repressing transcription of target genes or key enzymes (such as AP-1, PTEN, DAPK2, UP-1, p21WAF/CKN1A) that are critical for differentiation of hematopoietic cells. This is first described in eukaryotes.

Keywords: Gene transcription; molecular model of RA, retinoic acid and retinoid pharmacology, Vitamin A.

Article Info: Received 30 November 2018; Revised 11 December; Accepted 24 December, Available online 15 January 2019



Cite this article-

Zhu G, Al-kaf AGA. Vitamin A, retinoic acid and tamibarotene, a front toward its advances: a review. Universal Journal of Pharmaceutical Research 2018; 3(6): 35-44.

DOI: <https://doi.org/10.22270/ujpr.v3i6.215>

Address for Correspondence:

George Zhu, The Institute of Oncology, Tehran University of Medical Sciences, Tehran, Iran, E-mail: sansan4240732@163.com

INTRODUCTION

The biologic potency of vitamin A has been known for near one century. In 1912, Frederick Gowd and Hopkins demonstrated that a unknown accessory factors found in milk, other than carbohydrates, proteins, and fats were necessary for growth in rats. Hopkins received a Nobel Prize for this discovery in 1929¹⁻². By 1913, one of these substances was independently discovered by Elmer McCollum and Merguerite Davis at the University of Wisconsin

Madison, and Lafayette Mendel³ and Thomas Burr Osborne at Yale University who studied the role of fats in the diet⁴. The "accessory factors" were termed "fat soluble" in 1918⁵ and later "Vitamin A" in 1920⁶. In 1931, Swiss chemist Paul Karrer described the chemical structure of vitamin A. Vitamin A was first synthesized in 1947 by two Dutch chemists, David Adriaan Van Dorp and Jozef Ferdinand Arens. In the early 1960s, retinoids were introduced in dermatology for treatment of ichthyosis⁷ and later for psoriasis and

acne⁸. In 1975, Vitamin A acid, and the development of the synthetic retinoids are the pioneering work of Bollag W and Ott F in Sweden⁹. *In vivo*, the fat soluble vitamin A (retinol) can be reversibly metabolised to the aldehyde (retinal) which can in turn, be further oxidised in a non-reversible manner to retinoic acid (RA). Enzymes that oxidize retinol to retinaldehyde belong to two classes: the cytosolic alcohol dehydrogenases (ADHs) belonging to the medium-chain dehydrogenases/reductase family; and microsomal short-chain dehydrogenases/reductases (retinol dehydrogenases, RDHs)¹⁰. The next step in RA synthesis is the oxidation of retinaldehyde to RA, which is carried out by three retinaldehyde dehydrogenases (RALDHs):RALDH1, RALDH2 and RALDH3^{10,11}.The orange pigment of carrots (beta-carotene) can be represented as two connected retinyl groups, which are used in the body to contribute to vitamin A levels¹².The physiological and biological actions of this class of substances centre on vision, embryonic development and production, cellular growth and differentiation, skin health,and maintenance of immune function. Initial studies had focused on vitamin A deficiency and its major consequences: night blindness and Xerophthalmia. Fridericia and Holm¹³ investigated the influence of dietary A in the rhodopsin of the retina. Clearly, the rats lacking the fat-soluble vitamin A had a defect in the function of visual purple.




Figure 1: Chemical structure of retinol, one of the major forms of Vitamin A

Yudkin¹⁴ achieved one of the earliest identifications of vitamin A as a component of the retina. Subsequently, Wald¹⁵ determined the amount of vitamin A present in pig retinas. Wald G^{16,17} was well established the visual cycle: light decomposed rhodopsin to retinal and opsin. Retinal could either recombine with opsin to reform rhodopsin or it converted to free retinol. Retinol could reform rhodopsin, but only in the presence of the RPE (Kuhne). The further structure and metabolism of retinoids implicated that retinaldehyde was the visual pigment. More recently, vitamin A and its metabolites play a key importance in embryo morphogenesis, cell differentiation and clinical practice. Figure 1, chemical structure of retinol, one of the major forms of vitamin A (Vitamin A-Wikipedia).

Vision cycle

Vitamin A is needed by the eye retina, 11-cis-retinal (a derivative of vitamin A) is bound to the protein "opsin" to form rhodopsin (visual purple) in rods cells¹⁷, the molecule necessary for both low light (scotopic vision). As light enters the eye, the 11-cis-retinal is isomerized to all-trans retinal in photoreceptor cells of the retina. This isomerization induces a nervous signal (a type of G regulatory protein) along the optic nerve to the visual center of the brain. After separating from opsin, the all-trans-retinal is recycled and converted back to the 11-cis-retinal form via a series of enzymatic reactions. The all-trans- retinal dissociates from opsin in a series of steps called photo-bleaching. The final stage is conversion of 11-cis-retinal rebind to opsin to reform rhodopsin in the retina¹⁵⁻¹⁷. Kuhne showed that rhodopsin in the retina is only regenerated when the retina is attached to retinal pigmented epithelium (RPE)¹⁷. As the retinal component of rhodopsin is derived from vitamin A, a deficiency of Vitamin A inhibits the reformation of rhodopsin and lead to night blindness. Within this cycle, all-trans retinal is reduced to all-trans retinol in photoreceptors via RDH8 and possible RDH12 in rods, and transported to RPE. In the RPE, all-trans retinol is converted to 11-cis retinol, then 11-cis retinol is oxidized to 11-cis-retinal via RDH5 with possible RDH11 and RDH11¹⁰. This represents each RDH for the roles in the visual cycle.

Embryonic development, cell growth and differentiation

The inclusion of retinoic acid in superfamily of steroid and thyroid hormones underlines its importance in the development and differentiation in normal tissues. Retinoic acid (RA) is lipophilic molecule that act as ligand for nuclear RA receptors (RARs),converting them from transcriptional repressor to activators^{11,18} in RA signaling pathway. It has been demonstrated that retinoic acid was identified as a morphogen (teratogen) responsible for the determination of the orientation of the limb outgrowth in chicken¹⁹, and its retinoic acid receptors (RARs) appear at early stage of human embryonic development in certain types of tissues^{19,20}. Vitamin A plays a role in the differentiation of this cerebral nerve system in *Xenopus laevi*. The other molecules that interact with RA are FGF-8, Cdx and Hox genes, all participating in the development of various structures within fetus. For instance, this molecule plays an important role in hindbrain development. Both too little or too much vitamin A results in the embryo: defect in the central nervous system, various abnormalities in head and neck,the heart, the limb, and the urogenital system²⁰. With an accumulation of these malformations, an individual can be diagnosed with DeGeorge syndrome¹¹. *In vitro*, all-trans retinoic acid (ATRA) stimulates at least two-fold the clonal growth of normal human CFU-GM and early erythroid precursor BFU-E²¹. Cis-RA stimulates clonal growth of some myeloid leukemia cells. In suspension culture, there was an increase in cell number at day 5 in the presence of RA in half of 31 samples, which suggest that RA may play a role in the proliferation and survival of certain leukemia clones *in vitro*²². In contrast to the enhancement of normal hematopoietic

proliferation, RA (10⁻⁶-10⁻⁹ mol/l) is capable of inducing differentiation of the F9 mouse teratocarcinoma, HL-60 cells^{23,24} and some blasts from patients with promyelocytic leukemia²³. Maximum HL-60 differentiation (90% of cells) occurs after a 6 day exposure to 10⁻⁶mol/l retinoic acid. Further *in vitro* studies found that retinoic acid induced differentiation of leukemic blast cells in only 2 of 21 patients with AML, both of these patients had promyelocytic variant²⁴. These data suggest that retinoids may induce maturation of promyelocytes. Retinoic acid also inhibits the proliferation of other dermatological malignant cells.

Maintenance of Immune homeostasis

There is a link between retinoid and immune homeostasis. In the presence of retinoic acid, dendritic cells located in the gut are able to mediate the differentiation of T cells into regulatory T cells^{25,26}, which implicate that vitamin A exerts its areas of immune response via its against "self" and the prevention of host damage. Vitamin A metabolite retinoic acid act as a key regulator of TGF-beta-dependent immune responses. Vitamin A is capable of inducing the IL-6-driven induction of proinflammatory T(H) 17 cells, promoting anti-inflammatory T reg cells differentiation, thus regulating the balance between pro- and anti-inflammatory immunity²⁶.

RETINOIC ACIDS IN APL TREATMENT

Acute promyelocytic leukemia (APL, M3 in the FAB subtype) represent 5% to 15% of cases of acute promyelocytic leukemia²⁷, with characteristic t(15;17) translocation. APL treatment was initial for 13-cis RA²⁸⁻³⁰, later currently all-trans RA³¹, and recent tamibarotene³². In retrospective analysis, 3 of 5 (60%) these initial reported cases with 13-cis RA obtained complete remission (CR). Two of five obtained a CR for 11 months²⁹ and 1 year³⁰ respectively, the similar to 20 months in isolated CR APL for all-trans RA then observation^{33,34}. Another one patient with 13-cis RA early died from disseminated *candidiasis*, while the peripheral blood count rose from 0.3x10⁹/l to 6.7x10⁹/l with 2.3x10⁹/l mature cells²⁸. Moreover, Castaigne S and Chomienne C³¹ reported that treatment with all-trans RA alone (45mg/m²/day) produced CR in 14 of 22 (63.6%) cases of APL. The results confirmed Chinese investigation. This also confirmed previous isolated case reports of remission induction with 13-cis RA. In literature, an isolated APL obtained CR after treatment with 13-cis retinoic acid first and repeated CR with ATRA in relapse³⁵. Accordingly, ATRA plus chemotherapy or ATRA plus ATO regimen is the standard of care³⁶. And more, 80% (4/5) CR in newly APL and 33% (4/12) CR in relapsed APL were achieved after treatment with 9-cis retinoic acid (L-GD1057) alone³⁷. The data suggest that 9-cis RA is also effective agent for remission induction. Long-term follow up data, the rates of CR were found from 72%³⁸-94.3%³⁹ following ATRA treatment. Unlike other leukemia, APL has a very good prognosis, with long-term survival rates up to near 70%-90%⁴⁰. Based on the total of 2080 APL with ATRA combination protocol from seven larger cohort of study^{36,38,39,41-44},

the 3-year (range 1-115 months) disease-free survival (DFS) and overall survival (OS) were 87.7% and 90.6% respectively⁴¹; 6-year overall survival and disease-free survival in CR patients 83.9% and 68.5% respectively⁴⁴; 10-12 year survival about 68.9 - 77% (66.4- 71.4%)^{36,42}. But inclusion of early death⁴⁵, a total of another 1400 APL between 1992 and 2007, and the overall early death rate was 17.3%. The 3-year OS improved from 54.6% to 70.1% and a significantly lower in patients aged over 55 years (only 46.4%)⁴⁶; 5-year overall and disease-free survival rates of 51.6% and 50.1% respectively (73 APL unpublished data in 501 army hospital, Tehran, 1995-2015); 6 year OS 62% rates⁴⁷. Thus, the 10-year cumulative incidence of deaths in CR was 5.7%, 15.4% and 21.7% in younger than 55, 55 to 65, and older than 65 years, respectively⁴². Nowadays, a lot of cohort trials on using tamibarotene, 61.5% (24/39) achieved CR including 5 newly APL and 13 relapse APL twice or more³². Among 269 APL with CR underwent maintenance random, 4-year relapse-free survival rate was 84% (ATRA) and 91% (Tamibarotene). In 52 high risk patients, this becomes significant: 50% for ATRA, 87% for tamibarotene⁴⁸. In comparative analysis among those relapsed APL⁴⁹, 80% (28/35) achieved CR and 22.86% CRm in tamibarotene - ATO versus 54.2% (19/35) CR with only 2.86-3.7% CRm in ATRA - ATO regimen. From another 20 patients with relapsed APL, ATRA did not seem to significantly improve the response to ATO in patients relapsing from APL⁵⁰. In particular, appreciable benefits of tamibarotene-ATO regimen might occur at significantly lower frequency of leukocytosis with development of retinoic acid syndrome, an important adverse reaction during treatment of APL. Therefore, Tamibarotene demonstrated more efficacy in both untreated APL patients and relapsed who have been treated with ATRA and chemotherapy, especially as novel strategy in relapsed APL in Japan and others^{49,51,52}. This is encouraging perspective.

RARs Structure

The retinoic acid receptors (RAR) belong to the large family of ligand responsive gene regulatory proteins that includes receptors for steroid and thyroid hormones⁵³. There are three retinoic acid receptors (RAR), RAR α , RAR β and RAR γ which are conserved throughout vertebrates encoded by their different RAR (chr 17q21, chr 3p24 and chr12q13) gene, respectively. The RARA contains 462 amino acids (aa)^{54,55}, RARB consists of 455aa⁵⁶ and RARG contains 454aa⁵⁷, respectively. The RAR is a type of nuclear receptor which acts as a transcription factor that is activated by both all-trans RA and 9-cis RA. The RARs have different functions and may activate distinct target genes. The RARA is expressed in a wide variety of different hematopoietic cells^{54,55}; the RAR β in a variety of epithelial cells; and the RAR γ in differentiation of squamous epithelia and human skin tissue^{56,57}. All RARs contain a variable N-terminal region (A/B), a highly conserved cysteine-rich central domain (C) responsible for the DNA binding activity, and a relatively well-conserved C-terminal half (E) functionally its role in ligand binding and nuclear

translocation. These three main domain are separated by a hinge region (D)^{18,53,58}. The central DNA binding domain (88-153aa) exhibits an array of cysteine residues compatible with the formation of two so-called zinc finger. Each of them a zinc atom tetrahedrally coordinated to four cysteine, and each of the hypothetical zinc finger is encoded by a separate exon of the receptor gene [Zinc finger 1, 88-108aa, Zinc finger 2, 124-148aa]⁵³⁻⁵⁸. The N-terminal zinc finger of the DNA binding domain confers hormone responsiveness to HREs, determining target gene specificity, and responsible for functional discrimination between HREs whereas the C-terminal zinc finger contains the sugar-phosphamide backbone of the flanking sequences⁵⁸.




Figure 2: pml/RARα fusion in differentiation block at promyelocyte stage in transgenic mice(Figure from He LZ, et al., Proc Natl Acad Sci USA, 1997, 94:5302-07)[74]

Oncogenic pml/RARα act as constitutive transcriptional repressor that blocks neutrophil differentiation at the promyelocyte stage

Acute promyelocytic leukemia (APL) is a clonal expansion of hematopoietic precursors blocked at the promyelocytic stage. Approximately 98% of APL, RARα translocates and fuses with the PML gene on chromosome¹⁵. The resulting RAR chimeric genes encode pml/RARα fusion protein, which is specifically expressed in the promyelocytic lineage^{59,60}. In addition to oncogenic receptor derivative pml/RARα^{18,61-63}, the translocation involves oncogenic TBL1XR1-RARB⁶⁴ and NUP98/RARG⁶⁵, and oncogenic PML-RARG⁶⁶ which share high homolog (90%) of three RAR family that were also detected in APL rare cases. Most studies have shown that PML-RARα is an oncogenic transcription factor forming in APL. Without its ligand, retinoic acid (RA), PML-RARα functions as a constitutive transcriptional repressor, abnormally associating NcoR/HDACs complex and blocking hematopoietic differentiation. In the presence of pharmacological concentration of RA, RA induce the corepressors NcoR/HDACs dissociation from PML-

RARα, thereby PML-RARα activates transcription and stimulate differentiation^{18,61,67}. *In vitro* by using a dominant negative RAR construct transfected with interleukin 3(IL-3)-dependent multipotent hematopoietic cell line(FDCP mix A4) and normal mouse bone marrow cells, GM-CSF induced neutrophil differentiation was blocked at the promyelocyte stage. The blocked promyelocytes could be induced to terminally differentiate into neutrophils with supraphysiological concentration of ATRA⁶⁸. Similarly, over expression of normal RARα transduced cells displayed promyelocyte like morphology in semisolid culture, and immature RARα transduced cells differentiate into mature granulocytes under high dose of RA(10-6M)⁶⁹. Moreover, mutation of the N-CoR binding site abolishes the ability of PML-RARα to block differentiation^{70,71}. Therefore, ectopic expression of RAR fusion protein in hematopoietic precursor cells blocks their ability to undergo terminal differentiation via recruiting nuclear corepressor N-CoR/histone deacetylase complex and histone methyltransferase SUV39H1⁷². *In vivo*, transgenic mice expressing PML-RARα fusion can disrupt normal hematopoiesis, give sufficient time, develop acute leukemia with a differentiation block at the promyelocytic stage that closely mimics human APL (APL-like syndrome, see Figure 2) even in its response to RA in many studies. These results are conclusive *in vivo* evidence that PML/RARα is etiology of APL pathogenesis⁷³⁻⁷⁹. Structure and function analysis of pml/RARα uncovered that RAR component of the fusion protein is indispensable for its ability to impair terminal differentiation, and resolved the pml/RARα as constitutive repressor in differentiation block^{18,61,80-92}. PML-RARα retains both DNA binding domains and ligand binding domains of RARα. RARα is a member of nuclear receptors that bind to specific-RARE as heterodimers with RXR. By using RARα promoter-driven receptor plasmid containing RARE, the chimeric pml/RARα fusion reduces the induction of transcription by RA from a RARE by 50-90% in Hepa G cells⁵⁹. Many other two groups have further shown that PML-RARα act as strong transcriptional repressor in inhibiting transcription from RAREs to a great content than RARα, which may be critical for differentiation block in APL. In Rousselot's group experiments, HL-60 cells transfected with 15-30ug of PML-RARα fusion in culture show no features of granulocytic differentiation after 7 days of incubation with 10-7, 10-6 M RA(5.5-9.5% of differentiated cells by the NBT test). At 5ug of PML-RARα plasmid concentration, the blockage of RA-dependent myeloid differentiation could be overcomes with high doses (10-6M) of RA (99% of differentiated cells by NBT test) [Figure 3]. The results clearly indicate that PML-RARα mediated transcriptional repression, as well as PML-RARα oncoprotein blocks RA-mediate promyelocyte differentiation. By using *Xenopus oocyte system* to uniquely the comparison of the transcriptional properties of RAR and PML-RARα is due to the lack of endogenous nuclear receptors and the opportunity to evaluate the role of chromatin in transcriptional regulation.




Figure 3: Expression of pml-RARα in HL-60 cells: blocks ATRA-induced promyelocytic differentiation (in the presence of 10^{-7} M RA, top), and transcriptional repressive properties of pml-RARα in human myeloid cells as β RARE-luc assay (bottom) (Figure from Rousselot P, Oncogene, 1994, 9:545-551)[80]

The experimental results demonstrated that, indeed, PML-RARA is a stronger transcriptional repressor that is able to impose its silencing effect on chromatin state even in the absence of RXR. Only pharmacological concentration of RA, pml/RARA become transcriptional activator function⁶⁷. Moreover, ATRA treatment overcomes the differentiation block through dissociation of corepressor complexes from pml/RARA and transcription activation, thereby induces pml-RARA degradation, and subsequently promotes promyelocytic differentiation. *In vitro* experiments, ATRA induce pml-RARA itself cleavage into a 85-97kd delta PML-RARA product (a truncated pml/RARA form) in RA sensitive NB4⁹³⁻⁹⁶ [Figure 4]. Delta PML-RARA is not formed in ATRA differentiation resistant NB4 subclones^{93,96}, which indicate that the loss of PML/RARA may be directly linked to ATRA-induced differentiation^{93,96}. This induction of PML-RARA cleavage and degradation by RA (ATRA, 9-cis RA, Am80) involve the proteasome-dependent⁹³⁻⁹⁵ and caspase mediated pathway⁹⁷, or independent of proteasome and caspase cleavage⁹⁶, and possibly ubiquitin-activating enzyme E1-like (UBE1L) induction in NB4 cells. This is reason that proteasome inhibitor MG-132 and caspase inhibitor ZVAD do not block ATRA-induced pml/RARA cleavage and differentiation whereas this delta pml-RARA is blocked by RARA itself antagonist Ro-41-5253⁹⁶. The proteasome-dependent pml/RARA degradation, by using proteasome inhibitor lactacystin test, allows APL cells to differentiation by relieving the differentiation block⁹⁴. These data suggest a set of multiple molecular mechanisms for restoration by RA induced myeloid differentiation in APL cells. Next we further examine the pml/RARA three region functions; *in vitro* deletion of the RARA DNA binding domain decreased the ability of pml/RARA to inhibit Vit D3 and TGF-induced the myeloid precursor U937 and TF-1 cell differentiation⁷⁰. This is also supported by functional

analysis of DNA binding domain artificial mutation *in vitro*. The RARA zinc finger is a sequence-specific DNA binding through which RARA contacts the RA target genes.




Figure 4: Delta pml/RARA cleavage products independent of proteasome and caspase in the presence of ATRA (a, b), and pml/RARA act as transcriptional repressor even in the presence of ATRA (0.01 μ M, 1 μ M) in RARE-tk-luc assay while delta pml/RARA is less potent activator of RARE-tk-leu activation than wild-type RARA (c) in NB4 cells (Figure from Jing Y, Oncogene, 2003, 22:4083-91)[96]

Moreover, deletion of PML coiled-coil region also blocked the differentiation capacity of TF-1 cells⁷⁰. The coiled-coil region directs the formation of pml/RARA homodimers tightly interact with the N-CoR/HDACs complex, so that transcriptional de-repression cannot occur at RARA target gene promoter even if the presence of ATRA [RA resistant^{18,90}]. *In vitro*, using established subclones of NB4 resistant to both ATRA and 9-cis RA, they were significantly less able to stimulate transcription of a RARE driven CAT-reporter gene induction by ATRA and showed altered DNA binding activity on a RARE⁹⁸. In the resistant cases, mut PML stabilizes PML-RARA⁹⁹. PML-RARA with ligand-binding domain (LBD) mutation, ligand RA binding with LBD is impaired. Trichostatin A (TSA), known as HDAC inhibitor, antagonize HDAC activity and thereby enhance histone acetylation resulting in open chromatin state⁸⁶. TSA proved useful in therapeutic targeting of transcription in two APL patients^{100,101}. These results have clearly shown that PML protein dimerization and RARA DNA binding domain are indispensable for the myeloid precursors differentiation which was blocked by PML/RARA, and eventually leukemic transformation.




Figure 5: Molecular model of the gene regulation of retinoic acid (RA) action

(George Zhu, January 1991, revised in 2012). Schematic alignment of the receptor protein. The two highly conserved regions, identified as the putative DNA-binding (C) and hormone-binding (E), a hinge region (D) and the non-conserved variable NH2-terminus (A/B) as described above. CAT: CAAT box, CCAAT-enhancer binding proteins (or C/EBPs); GC: GC box; TATA: TATA box. Note: In APL cells, PML-RARa fusion point is located in the first 60 amino acids from the N-terminus (A/B) of RARa. (Figure from Zhu G, *Curr Pharm Biotechnol*, 2013, 41(9):849-858) [18,112,113]

In accordance, the pml/RARa/RXR target genes are thought to block differentiation by constitutively silencing a set of RA-responsive genes in the control of hematopoietic precursor cells. These include Jun/Fos/Ap-1, C/EBPa, C/EBPepsilon, DAPK2/PU.1, HOXA7, HOXA9, HOXA10, MEIST, SAP30, p21WAF/CCKN1A^{81,102-106}. Five major transcription factors, Ap-1⁸¹, C/EBPepsilon^{102,103}, Pu.1/DAPK2¹⁰⁴, PTEN¹⁰⁵, and p21WAF/CCKN1A¹⁰⁶, directly regulate genes important in myeloid differentiation, such as G-CSFR, CD11b, Myeloperoxidase, Gr-1 or Mac-1. PML/RARa fusion is oncogenic transcriptional repressor of five genes. Inhibited expression or functions of these five transcription factors lead to a block in myeloid differentiation, which is a hallmark of APL. Importantly, restoring DAPK2 expression in PU.1 knockdown APL cells partially rescued neutrophil differentiation¹⁰⁷. DAP-Kinase is a calcium/Calmodulin (CaM)-dependent, cytoskeletal-associated protein kinase (ser/thr). In addition, DAPK2 interacts with other cyclin-dependent kinase inhibitors such as p15INK4b and p21WAF1/CIP, which is needed for the cell-cycle arrest in terminal differentiation of neutrophils. Moreover, DAPK2 can bind and activate the key autophagy gene beclin-1¹⁰⁷. PU.1, an ETS transcription factor known to regulate myeloid differentiation. Silencing of PU.1 in the adult hematopoietic tissue produces dysfunctional stem cells and impairs granulopoiesis by inducing a maturation block. Overexpression of PU.1 overcomes the differentiation block in SCa 1+/Lin- HSC with transduction of PML/RARa fusion, as measured by the Gr-1 and Mac-1 expression¹⁰⁸. Thus, pml/RARa represses PAPK2/PU.1-mediated transcription of myeloid genes in APL, linking a novel autophagy mechanism of pml/RARa degradation¹⁰⁹.

Molecular model of the gene regulation of retinoic acid action in APL

The molecular mechanism of retinoic acid action in APL has been proposed in several publications^{86,89,110}. Based on review more researches publications^{27-52,53-109}, the detail mechanism has also been described by Zhu^{18,111,113}. In the absence of RA, RARa functions as a nuclear receptor that binds to specific DNA sequence called RA responsive element (RARE: AGGTCA motif) in target gene promoter, normally as heterodimer with RXR. RAR-RXR heterodimer induce transcriptional repression throughout chromatin remodeling by recruiting corepressor N-CoR/SMRT, and histone deacetylases (HDACs) and histone methyltransferases. Physiological levels of RA induce the dissociation of corepressor complexes and allow for the recruitment of co-activators, including histone acetylases. Consequentially, RA treatment leads to transcriptional activation, thereby trigger expression of genes involved in myeloid differentiation^{11,18,67,84,90}. In special APL, oncogenic pml/RARa binds to consensus sequence of target gene promoter primarily as homodimer, also as a heterodimer with RXR. PML-RARa behave as a constitutive transcriptional repressor of RARE-containing genes^{18,61,67,80-92,102-106} through tightly binding with the corepressor complexes, and promiscuously interfering with RARa and retinoic acid signaling, thereby inducing a differentiation block at promyelocytic stage which can be overcome with supraphysiological doses of 9-cis or/and ATRA ligand. As an approach to APL treatment, one possible the action of retinoic acid (RA), A consensus sequence (TCAGGTCA motif) has been postulated for thyroid hormone (TRE) and retinoic acid responsive element (RARE)-containing in the promoter region of target genes¹¹⁴. High dose of RA-RARE-PML/RARa complexes in intracellular localization appears to

relieve repressors from DNA-bound receptor^{18,70,82,115-117}, including the dissociation of corepressor complexes N-CoR, SMRT and HDACs from PML-RAR α or PML-RAR α /RXR^{18,71,82,84,90}. Also release PML/RAR α - mediated transcription repression⁸⁷. This transcriptional derepression occurs at RAR α target gene promoter^{18,84,90}. Consequentially, PML-RAR α chimera converted receptor from a repressor to a RA-dependent activator of transcription^{81,85,87,90,92}. The resulting pml-RAR α oncoprotein proteolytic degradation occurs through the autophagy-lysosome pathway¹⁰⁹ and the ubiquitin SUMO-proteasome system(UPS)⁹³⁻⁹⁶ as well as caspase 3⁹⁷, or lysosomal protease (cathepsin D) enzyme or/and EI-like ubiquitin-activating enzyme (UBE1L) induction⁸³. An effect is to relieve the blockade of pml/RAR α -mediated RA dependent promyelocytic differentiation, and retinoic acid (9-cis RA, ATRA, Am80) in APL therapy (Figure 5, Zhu, March 1990- January 1991, revised in 2012). Here, RA can overcome the transcriptional repressor activity of pml/RAR α ^{18,61,67,80-92,102-106}. The oncogenic pml/RAR α uncover a pathogenic role in leukemogenesis of APL through blocking promyelocytic differentiation. This oncogenic receptor derivative pml/RAR α chimera is locked in their "off" regular mode thereby constitutively repressing transcription of target genes or key enzymes (such as AP-1, PTEN, DAPK2, UP.1, p21WAF/CCKN1A)^{81,102-106} that are critical for differentiation of hematopoietic cells. This is first described in eukaryotes.

CONCLUSION

To date, the discovery of the fat soluble vitamin A has been known for over 100 years, more scientists have made their contribution in this field. Vitamin A and its derivative retinoic acids (RA) have been shown a broad variety of biological actives in human, such as vision, embryonic development, cellular growth and differentiation, and immune function. These precise functions of RA are mediated by their RA receptors (RAR). Retinoic acids have therapeutic benefits in the past five decades the advances in treatment of skin diseases and acute promyelocytic leukemia (APL). More than ten to twenty laboratories are trying to uncovering the molecular model of RA action in APL, the detail mechanism had also been proposed by Zhu in January 1991. This earlier hypothesis have now been demonstrated by structure and functional analysis of oncogenic pml/RAR α chimera protein *in vitro* and *in vivo* in numerous studies, and partially mentioned above in this paper. This appears to be its centre and its main aim in this researching review. This is key important useful paradigm and perspective in our highlight on 'genetic dissection of gene regulation in clinical cancer biology'; Professor LP Wu says 5 years ago. Whether silencing of these RARE-responsive target genes such as myeloid transcription factors C/EBP α , PU.1 or other unknown key enzymes that are really crucial for neutrophil differentiation needs to further identification and under investigation.

CONFLICTS OF INTEREST

The author declares that there is no conflict of interest regarding the publication of this paper.

AUTHOR'S CONTRIBUTION

The manuscript was carried out, written, and approved in collaboration with all authors.

ACKNOWLEDGEMENTS

Authors are thankful for the valuable suggestions of Prof. Dr. Kapil Kumar, Head of Department, Global Institute of pharmaceutical education and research, Kashipur, Uttarakhand, India.

REFERENCES

1. Semba RD. On the 'discovery' of vitamin A. *Annal Nutri Meta* 2012; 61(3):192-8. <https://doi.org/10.1159/000343124>
2. Wolf G. Discovery of Vitamin A. *Encyclopedia of life Sciences* 2001. <https://doi.org/10.1038/npg.2020els.0003414>
3. Osborne TB, Mendel LR. The relation of growth to the chemical constituents of the diet 1913;15:311-26 <https://doi.org/10.1002/fes3.64>
4. McCollum EV, Davis M. The necessary of certain lipins in the diet during growth 1913;15:167-175. <https://doi.org/10.1111/j.1753-4887.1973.tb07065.x>
5. McCollum EV, Davis M. The nature of dietary deficiencies of rice loss. *J Biol Chem* 1915;181-230.
6. Drummond JC. The nomenclature of so-called accessory food factors (vitamins). *Biochem J* 1920; 14:660-661. <https://doi.org/10.1042/bj0140660>
7. Stuetgen G. On the local therapy of keratosis with vitamin A acid. *Dermatologica* 1962; 124:65-80. PMID: 13917997
8. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. *Arch Dermatol.* 1969; 99:469-76. PMID: 4238828
9. Bollag W, Ott F. Vitamin A acid in benign and malignant epithelial tumours of the skin. *Acta Dermato-Venereol.* 1975; 74:163. PMID: 816129
10. Parker RO, Crouch RK. Retinol dehydrogenases (RDHs) in the visual cycle. *Exp Eye Res* 2010; 91(6):788-92. <https://doi.org/10.1016/j.exer.2010.08.013>
11. Rhinn M, Dolle P. Retinoic acid signaling during development. *Development* 2012; 139(5):843-58 <https://doi.org/10.1242/dev.065938>
12. DeMan J. Principles of food chemistry (3rd ed). Maryland: Aspen Publication Inc. P358. ISBN 083421234
13. Fridericia LS, Holm E. Experimental contribution to the study of the relation between night blindness and malnutrition. *Am J Physiol* 1925;73:63-78. <https://doi.org/10.1001/jama.1932.27320500001008>
14. Yudkin AM. The presence of vitamin A in the retina. *Arch Ophthalmol* 1931; 6:510- 517. PMID: 16692892
15. Wald G. Vitamin A in eye tissues. *J Gen Physiol* 1935; 18:905-915. <https://doi.org/10.1085/jgp.18.6.905>
16. Wald G. Carotenoids and the visual cycle. *J Gen Physiol* 1935; 19:351-71. <https://doi.org/10.1085/jgp.19.2.351>
17. Wolf G. The discovery of the visual function of vitamin A. *The J Nutr* 2001;131(6):1647-50 <https://doi.org/10.1093/jn/131.6.1647>
18. Zhu G, Mische SE, Seigner B. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology. *Curr Pharm Biotech* 2013; 13(9):849-858. <https://doi.org/10.2174/1389201015666140113095812>
19. Maden M. The role of retinoids in developmental mechanisms in embryos. *Fat-Soluble Vitamins* 1995; 30:81-111. https://doi.org/10.1007/978-1-4899-1789-8_4
20. Paulsen DF. Retinoic acid in limb-bud outgrowth: Review and hypothesis. *Anat Embryol* 1994; 190(5):399-415. <https://doi.org/10.1007/BF00235487>

21. Dour D, Koeffler HP. Retinoic acid enhances growth of human early erythroid progenitor cells *in vitro*. J Clin Invest 1982; 69:1039. <https://doi.org/10.1172/JCI110507>
22. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L. All-trans retinoic acid in acute promyelocytic leukemia II. *In vitro* studies. Structure-function relationship. Blood 1990;76:1710. <https://doi.org/10.1038/sj.onc.1204763>
23. Dour D, Koeffler HP. Retinoic acid inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 1982;69:277. <https://doi.org/10.1172/JCI110450>
24. Breitman TR, Selonic SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA. 1981; 57:10000-10001. <https://doi.org/10.1073/pnas.77.5.2936>
25. Sun CM, Hall JA, Blank KB et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med 2007;204(8):1775-85. <https://doi.org/10.1084/jem.20070602>
26. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:250-60. <https://doi.org/10.1126/science.1145697>
27. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of the acute leukemias. Br J Haematol 1976; 33:451-58. <https://doi.org/10.1111/j.1365-2141.1976.tb03563.x>
28. Flynn TJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. Retinoic acid treatment of acute promyelocytic leukemia: *in vitro* and *in vivo* observation. Blood 1983; 62:1211-17. <https://doi.org/10.1056/NEJMoa1300874>
29. Nilsson B. Probable *in vivo* induction of differentiation, retinoic acid of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1984; 57:365-71. <https://doi.org/10.1371/journal.pmed.0020012>
30. Fontana JA, Rogers HS, Durham JP. The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 1986;57:209-217. [https://doi.org/10.1002/1097-0142\(19860115\)57:2<209::aid-cnrc2820570204>3.0.co;2-k](https://doi.org/10.1002/1097-0142(19860115)57:2<209::aid-cnrc2820570204>3.0.co;2-k)
31. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. clinical results. Blood 1990; 76:17. <https://doi.org/10.1056/NEJM199105163242002>
32. Tobita T, Takashita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997; 90(3):967-973. PMID: 9242525
33. Zhu G, Saboor-Yaraghi A, Dharmadhikari D, et al. A pilot study of chemotherapy and traditional plant medicine in hematology malignancy: report of third-four cases. Hematol Med Oncol 2017;2(2):1-3. <https://doi.org/10.15761/HMO.1000122>
34. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107(9):3469-73 <https://doi.org/10.1182/blood-2005-10-4006>
35. Haferlach T, Loeffler H, Glass B, et al. Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse. Clin Investig 1993; 71(10):774-79. <https://doi.org/10.1007/BF00190317>
36. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114(25):5126-35. <https://doi.org/10.1182/blood-2009-07-216457>
37. Soignet SL, Benedetti F, Fleischauer A, et al. Clinical study of 9-cis retinoic acid (LGD 1057) in acute promyelocytic leukemia. Leukemia 1998; 12:1518-21. https://doi.org/10.1007/978-1-59259-383-5_13
38. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-28. <https://doi.org/10.1056/NEJM199710093371501>
39. Avvisate G, Lo-coco F, Paoloni FP and for the GIMEMA, AIEOP, and EIRTC cooperative groups. AIDA0493 protocol for newly diagnosed acute promyelocytic leukemia, very long-term results and role of maintenance. Blood 2011; 117(18):4716-25. <https://doi.org/10.1182/blood-2010-08-302950>
40. Cicconi L, Lo-coco F. Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol 2016; 27(8):1474-81. <https://doi.org/10.1093/annonc/mdw171>
41. Au WY, Kumana CR, Lee HKK, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia. A 10-year follow-up study. Blood 2011; 118:6535. <https://doi.org/10.1182/blood-2011-05-354530>
42. Ader L, Guerci A, Raffoux E, and for the European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy, the European APL group experience. Blood 2010; 115:1690-96. <https://doi.org/10.1182/blood-2009-07-233387>
43. Iland H, Bradstock K, Seymour J. The Australasian Leukemia and lymphoma group. Results of the APLM3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematol 2011; 97:227-234. <https://doi.org/10.1182/blood-2012-02-410746>
44. Asou N, Kishimoto YJ, Kiyoi H, and for Japan Adult leukemia study Group. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARA transcript after consolidation therapy. The Japan adult leukemia study group (JALSG) APL97 study. Blood 2007; 110:59-66. <https://doi.org/10.1182/blood-2006-08-043992>
45. Estey EH. Newly diagnosed acute promyelocytic leukemia. Arsenic moves front to center. J Clin Oncol 2011;29:2743. <https://doi.org/10.1200/JCO.2011.35.1031>
46. Park JH, Qiao BZ, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-54. <https://doi.org/10.1182/blood-2011-04-346437>
47. Lehmann S, Ravn A, Carlsson L. Continuing high early death rate in acute promyelocytic leukemia, a population-based report from the Swedish adult acute leukemia registry. Blood 2011; 25(7):1128-43. <https://doi.org/10.1038/leu.2011.78>
48. Shinagawa K, Yanada M, Sakura T, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol. 2014;32(33):3729-35. <https://doi.org/10.1038/s41375-018-0233-7>
49. Wang JX, Mi YC, Jiang B, et al. Tamibarotene compared to all-trans retinoic acid (ATRA) as add-on to arsenic trioxide(ATO) in subjects with relapsed acute promyelocytic leukemia(APL). Blood 2015. <https://doi.org/10.1182/blood.V126.23.220.220>
50. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21:2326-34. <https://doi.org/10.3892/ol.2013.1643>
51. Kojima M, Ogiya D, Ichiki A, et al. Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene. Leuk Res Rep 2016; 5:11-13. <https://doi.org/10.1016/j.lrr.2016.01.001>
52. Asou N. Retinoic acid, all-trans retinoic acid (ATRA) and Tamibarotene. Chemotherapy for leukemia 2017:183.
53. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:899-95. <https://doi.org/10.1126/science.3283939>

54. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for morphogen retinoic acid. *Nature* 1987; 330:624-29. <https://doi.org/10.1038/330624a0>
55. Petkovich M, Brand N, Krust A, Chambon P. A human retinoic acid receptors which belongs to the family of nuclear receptors. *Nature* 1987; 330:444-450. <https://doi.org/10.1038/330444a0>
56. Brand N, Petkovich M, Krust A, Chambon P, de The H, Marchio A, Tiollais P, Dejean A. Identification of a second human retinoic acid receptor. *Nature* 1988;332:850-53. <https://doi.org/10.1038/332850a0>
57. Lehmann JM, Hoffmann B, Pfahl M. Genomic organization of the retinoic acid receptor gamma gene. *Nucleic Acids Res* 1991; 19(3):573-8. <https://doi.org/10.1093/nar/19.3.573>
58. Krust A, Kastner PH, Petkovich M, Zelent A, Chambon P. A third human retinoic acid receptor, hRAR- γ . *Proc Natl Acad Sci USA* 1989; 86:5310-14. <https://doi.org/10.1073/pnas.86.14.5310>
59. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RARA fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell* 1991; 66:675-84. [https://doi.org/10.1016/0092-8674\(91\)90113-D](https://doi.org/10.1016/0092-8674(91)90113-D)
60. Zhu Y. Retinoic acid receptor alpha gene rearrangement as specific marker of acute promyelocytic leukemia and its use in the study of cell differentiation. *Zhonghua Yi Xue Za Zhi*. 1992; 72(4); 229-33. PMID: 1327453
61. Hauksdottir H, Privalsky ML. DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. *Cell Growth Differ* 2001; 12:85-98. PMID: 11243468
62. Zhu G. Oncogenic receptor hypothesis (1989-91) VOA (Voice of America).1992; 12:31. <https://doi.org/10.19080/JETR.2019.04.555643>
63. Zhu G. Five to ten survivors of patients with advanced cancers following chemotherapy and traditional medicine. *JCCM*. 2009, 4(9):512-519.
64. Osumi T, Tsujimoto SI, Tamura M, *et al.* Recurrent RAR β -translocations in acute promyelocytic leukemia lacking RARA translocation. *Cancer Res* 2018; 78(16):4452-8. <https://doi.org/10.1158/0008-5472.CAN-18-0840>
65. Such E, Cervera J, Valencia A, *et al.* A novel NUP98/RSRG fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. *Blood* 2011; 117(1):242-45. <https://doi.org/10.1182/blood-2010-06-291658>
66. Ha JS, Do YR, Ki CS, Jeon DS, *et al.* Identification of a novel PML-RARG fusion in acute promyelocytic leukemia. *Leukemia* 2017; 31(9):1992-95. <https://doi.org/10.1038/leu.2017.167>
67. Segalla S, Rinaldi L, Kalstrup-Nielsen C, *et al.* Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties. *Mol Cell Biol* 2003; 23(23):8795-8808. <https://doi.org/10.1128/MCB.23.23.8795-8808.2003>
68. Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at promyelocytic stages. *PNAS* 1993; 90(15):7153-57. <https://doi.org/10.1073/pnas.90.15.7153>
69. Onodera M, Kunisada T, Nishikawa S, *et al.* Overexpression of retinoic acid receptor alpha suppresses myeloid cell differentiation at the promyelocyte stage. *Oncogene* 1995; 11(7):1291-8. PMID: 7478549
70. Grignani F, Testa U, Rogaia D, *et al.* Effects on differentiation by the promyelocytic leukemia pml/RAR alpha protein dimerization and RAR alpha DNA binding domains. *EMBO J* 1996; 15(18):4949-58. PMID: 8890168
71. Grignani F, De Matteis S, Nervi C, Tomassoni L, Pelicci PG, *et al.* Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukemia. *Nature* 1998; 391:815-18. <https://doi.org/10.1038/35901>
72. Carbone R, Botrugn OA, Ronzoni S, Insinga A, Pelicci PG, *et al.* Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. *Mol Cell Biol* 2006;26(4):1288-96. <https://doi.org/10.1128/MCB.26.4.1288-1296.2006>
73. Brown D, Kogan S, Lagasse E, Weissman L, Alcalay M, *et al.* A PML/RARA transgenic initiates murine acute promyelocytic leukemia. *Proc Natl Acad Sci USA* 1997; 94:2551. <https://doi.org/10.1073/pnas.94.6.2551>
74. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, *et al.* Acute leukemia with promyelocytic features in pml/RARA transgenic mice. *Blood* 1997; 94:5302. <https://doi.org/10.1073/pnas.94.10.5302>
75. Grisolan JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing pml-RARA under control of Cathepsin G regulatory sequences. *Blood* 1997; 89:376-87. PMID: 9002938
76. Kelly LM, Kutok JL, Williams LR, Boulton CL, Amaral SM. PML/RAR alpha and FLT3-ITD induces APL-like disease in a mouse model. *Proc Natl Acad Sci USA* 2002; 99:8283-8. <https://doi.org/10.1073/pnas.122233699>
77. Minucci S, Monesbiroli S, Giavara S, Ronzoni J, Pelicci PO. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. *Blood* 2002; 100(8):2989-95. <https://doi.org/10.1182/blood-2001-11-0089>
78. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, *et al.* High penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RAR alpha expression. *Blood* 2002; 102(5):1857-65. <https://doi.org/10.1182/blood-2002-12-3779>
79. Sukhai MA, Wu X, Xuan Y, Zhang T, Reis PP, Dube K, Pandolfi PP. Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR alpha. *Oncogene* 2004; 23(3):665-78. <https://doi.org/10.1038/sj.onc.1207073>
80. Rousselot P, Hardas B, Patel A, *et al.* The PML-RARA gene products of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. *Oncogene* 1994; 9(2):545-51. PMID: 8290265
81. Doucar V, Brockes JP, Yaniv M, de The H, Dejean A. The PML-retinoic acid alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. *Proc Natl Acad Sci USA* 1993; 90:9345-9. <https://doi.org/10.1073/pnas.90.20.9345>
82. He LZ, Guidez F, Tribioli C, Peruzzi D, Pandolfi PP, *et al.* Distinct interactions of PML-RARA and PLZF-RARA with Corepressors determine differential responses to RA in APL. *Nature Genetics* 1998; 18:126-135. <https://doi.org/10.1038/ng0298-126>
83. Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, *et al.* UBE1L is a retinoid target that triggers PML/RAR alpha degradation and apoptosis in acute promyelocytic leukemia. *Proc Natl Acad Sci USA* 2002; 99(6):3806-11. <https://doi.org/10.1073/pnas.052011299>
84. Villa R, Morey L, Raker VA, Burchbeck M, Gutierrez A, *et al.* The methyl-CpG binding protein MBD is required for PML-RARA fusion. *Proc Natl Acad Sci USA* 2006; 103(5):1400-05. <https://doi.org/10.1128/mcb.18.11.6538>
85. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, de The H, *et al.* Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. *Nature Medicine* 2008; 14:1333-42. <https://doi.org/10.1038/nm.1891>
86. Marstrand TT, Borup R, Willer A, Borregaard N, Sandelin A, *et al.* A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. *Leukemia* 2010; 24(7):1265-75. <https://doi.org/10.1038/leu.2010.95>
87. Lallemand BV, de The H. A new oncoprotein catabolism pathway. *Blood* 2010; 116:2200-2201. <https://doi.org/10.1182/blood-2010-07-294025>
88. Marinelli A, Bossi D, Pelicci PG, Minucci S. A redundant oncogenic potential of the retinoic acid receptor (RAR) alpha, beta and gamma isoforms in acute promyelocytic leukemia. *Leukemia* 2007; 21:647-50.

- <https://doi.org/10.1038/sj.leu.2404572>
89. Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. *J Exp Med* 2013;210(13):2793-802. <https://doi.org/10.1084/jem.20131121>
 90. Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid(ATRA) and arsenic trioxide(As₂O₃) in acute promyelocytic leukemia. *Int J Hematol* 2013;97(6):717-725. <https://doi.org/10.3390/ijms20143559>
 91. De Braekeleer E, Dout-Guilbert N, De Braeleleer M. RARA fusion genes in acute promyelocytic leukemia: a review. *Expert Rev Hematol* 2014; 7(3):347-57. <https://doi.org/10.1586/17474086.2014.903794>
 92. Jing Y. The PML-RARa fusion protein and target therapy for acute promyelocytic leukemia *Leuk lymphoma* 2004; 45:639-48. <https://doi.org/10.1080/10428190310001609933>
 93. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. *Blood* 1996; 88:2826-32. PMID: 8874178
 94. Yoshida H, Kitamura K, Tanaka K, et al. Accelerated degradation of PML-RARa oncoprotein by ATRA in APL: possible role of the proteasome pathway. *Cancer Res* 1996; 56(13):2945-48. PMID: 8674046
 95. Fanelli M, Minucci S, Gelmetti V, Nervi C, Pelicci PG. Constitutive degradation of pml/RAR through the proteasome pathway mediates retinoic acid resistance. *Blood* 1999; 93:1477-81. PMID: 10029573
 96. Jing Y, Xia L, Lu M, Waxman S. The cleavage product delta PML-RARa contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. *Oncogene* 2003; 22:4083-91. <https://doi.org/10.1038/sj.onc.1206568>
 97. Nervi C, Ferrara FF, Fanelli M, Rippon RM, Tomassini B, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARa fusion protein. *Blood* 1998; 92(7):2244-51. PMID: 9746761
 98. Rosenauer A, Raelson JV, Nervi C, et al. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. *Blood* 1996; 88(7):2671-82. PMID: 8839862
 99. Bellodi C, Kindle K, Bernassola F, Binsdale D, Cossarizza A, et al. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor alpha. *J Biol Chem* 2006; 281:14465-73. <https://doi.org/10.1074/jbc.M600457200>
 100. Warrell JrRP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor histone deacetylase. *J Natl Cancer Inst* 1998; 60:1621-25. <https://doi.org/10.1038/bjc.2016.36>
 101. McMullin MF, Nugent E, Thompson A, Hull D, Grimwade D. Prolonged molecular remission in PML-RARa-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate. *Leukemia* 2005; 19:1676-77. <https://doi.org/10.1038/sj.leu.2403883>
 102. Park DJ, Chumakov AM, Vuong PT, Chih DY, Koeffler HP, et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. *J Clin Invest* 1999; 103(10):1399-408. <https://doi.org/10.1172/JCI2887>
 103. Yamanaka R, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. *Proc Natl Acad Sci USA* 1998; 94:13187-192. <https://doi.org/10.1073/pnas.94.24.13187>
 104. Humbert M, Federzoni EA, Britschgi A, et al. The tumor suppressor gene DAPK2 is induced by the myeloid transcript factors PU.1 and C/EBPa during granulocytic differentiation but repressed by PML-RARa in APL. *J Leuk Biol* 2014; 95:83-93. <https://doi.org/10.1189/jlb.1112608>
 105. Noguera NI, Piredda ML, Taulli R, Catalano G, Angelini G, et al. PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. *Oncotarget* 2016;7(41):66386-397. <https://doi.org/10.18632/oncotarget.11964>
 106. Choi W-II, Yoon JH, Kim MY, Koh DI, Litch JD, et al. Promyelocytic leukemia zinc finger-retinoic acid receptor a(PLZF-RARa), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A(p21WAF/CKN1A) and tumor protein p53(TP53) gene. *J Biol Chem* 2014; 289:18641-656. <https://doi.org/10.1074/jbc.M113.538777>
 107. Mueller BU, Pabst T, Fos J, Petkovic V, Asou N. ATRA resolves the differentiation block in t(15;17) acute promyelocytic leukemia by restoring PU.1 expression. *Blood* 2006; 107:3330-38. <https://doi.org/10.1182/blood-2005-07-3068>
 108. Seshire A, Iger TR, French M, Beez S, Hagemeyer H. Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding. *Leukemia* 2012; 26:1338-47. <https://doi.org/10.1038/leu.2011.331>
 109. Isakson P, Bjoras M, Boe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARa oncoprotein. *Blood* 2010; 116:2324-31. <https://doi.org/10.1182/blood-2010-01-261040>
 110. Melnick A, Litch JD. Deconstructing a disease: RAR, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. *Blood* 1999; 93(10):3167-3215. PMID: 10233871
 111. Zhu G. A pilot study of small dosage of chemotherapy and traditional medicine in advanced cancers: report of twenty four cases. *Proceedings of 2nd biotechnology world congress, Dubai, UAE, February 18-21, 2013*; 98. <https://doi.org/10.15761/LBJ.1000115>
 112. Zhu G. Discovery of the molecular basis of retinoic acid action (retinoid signaling)- A genetic regulation of eukaryotes in transcription(Abstract). *Proceedings of 3rd biotechnology world congress, Dubai, UAE, February 10-12, 2014*; 97-98. <https://doi.org/10.19080/JETR.2019.04.555643>
 113. Zhu G, Saboor-Yaraghi AA, Yarden Y. Targeting oncogenic receptor: From molecular physiology to currently the standard of target therapy. *Advance Pharm J* 2017; 2(1):10-28. <https://doi.org/10.1038/s41392-019-0099-9>
 114. Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. *Nature* 1988; 336:263. <https://doi.org/10.1038/336262a0>
 115. Damm K, Thompson CC, Evans RM. Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. *Nature* 1989; 339:593. <https://doi.org/10.1038/339593a0>
 116. Graupner G, Wills KN, Tzukerman M, Zhang XK, Evans EM. Dual regulatory role for thyroid-hormone receptors allows control of retinoic-acid receptor activity. *Nature* 1989; 340:653. <https://doi.org/10.1038/340653a0>
 117. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. *Science* 1989; 245:371-78. <https://doi.org/10.1126/science.2667136>